XORTX Therapeutics (XRTX) Return on Capital Employed (2021 - 2023)

XORTX Therapeutics' Return on Capital Employed history runs 3 years deep, the most recent figure standing at 83.04% for Q3 2023.

• Quarterly Return on Capital Employed changed N/A year-over-year to 83.04% in Q3 2023, while the trailing twelve-month figure through Sep 2023 was 83.04% (changed N/A YoY) and the FY2023 annual result came in at 22.08%, up 5415.0% from the prior year.
• Return on Capital Employed was 83.04% for Q3 2023 at XORTX Therapeutics, down from 60.36% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 11.78% in Q4 2021 and bottomed at 83.04% in Q3 2023.
• A 3-year average of 53.81% and a median of 60.21% in 2022 frame the typical range for Return on Capital Employed.
• Peak annual rise in Return on Capital Employed reached 4828 bps in 2022, while the deepest fall reached 4828 bps in 2022.
• XORTX Therapeutics' Return on Capital Employed stood at 11.78% in 2021, then slumped by 410 bps to 60.06% in 2022, then sank by 38 bps to 83.04% in 2023.
• Business Quant data shows XRTX's Return on Capital Employed at 83.04% in Q3 2023, 60.36% in Q2 2023, and 60.06% in Q4 2022.